For men with prostate cancer the outlook on life is often quite bleak; many are given just months to live. Fortunately Johnson & Johnson has created a drug that reportedly extends the lives of patients a significant amount. That drug, Zytiga, became available in many areas just last month but long term study results have already begun to show up.
Zytiga officially became an approved medication in the United States just last month but Johnson & Johnson studies have shown that in most cases Zytiga is effective at extending the life of many advanced prostate cancer patients.
According to doctors the biggest problem with prostate cancer is that is spreads so quickly, even when compared to other cancers. Zytiga works by specifically targeting the hormones and proteins required for the prostate cancer to spread and thus Zytiga effectively slows the progression of the cancer substantially.
Unfortunately Zytiga still is not a treatment or cure for the cancer. Generally advanced prostate cancer is deadly unless caught early and as a result doctors have been focusing on any sort of medication that can slow the progression of the cancerous cells; thus far Zytiga has been the most effective though reports indicate that other possible medications are in testing as well. For now medical analysts are happy with the results from Zytiga and until a better option is researched or created there is unfortunately nothing better available; Zytiga is simply a way to prolong the lives of those who have little hope.